MRK241122P115000
- 13.67
- 0.000.00%
Merck & Co Newsroom
Patent cliff crisis resolved? merck (MRK.US) Keytruda subcutaneous injection version reaches primary endpoints in phase 3 trials.
Merck stated that in a key phase 3 trial, the subcutaneous version of the anti-PD1 drug achieved its primary objectives, performing comparably to the intravenously administered version approved by the FDA, and is a first-line option for lung cancer.
Merck & Co To Go Ex-Dividend On December 16th, 2024 With 0.81 USD Dividend Per Share
November 19th (Eastern Time) - $Merck & Co(MRK.US)$ is trading ex-dividend on December 16th, 2024.Shareholders of record on December 16th, 2024 will receive 0.81 USD dividend per share on January 8th,
Merck Readies New Keytruda Version Ahead of Major Regulatory Headwinds
Incyte Pares Some Losses on Report of Potential Merck Takeover Interest
Express News | Merck Is the Latest Industry Giant to Be Linked to a Takeover Bid for Incyte- Sky News Reporter Mark Kleinman on X
J.P. Morgan Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $145
Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients
Merck Raises Quarterly Dividend to 81c Vs. 77c >MRK
Express News | Merck Announces First-Quarter 2025 Dividend
Merck's Cancer Shot Works. Its Post-Keytruda Plans Are Shaping Up Again. -- Barrons.com
Merck announces positive trial results for the subcutaneous injection version of the cancer drug Keytruda.
On November 19, Glint reported that merck stated that its blockbuster cancer drug Keytruda's subcutaneous injection combined with chemotherapy has proven to be as effective as the intravenous injection, with the former's pivotal Phase III trial achieving dual primary pharmacokinetic endpoints. Merck indicated that it will discuss these results with global regulatory institutions. It is reported that the global best-selling drug Keytruda has annual sales of approximately 25 billion dollars, but it faces the challenge of patent expiration in 2028.
Express News | Nine-valent HPV vaccine is expanding to the male market.
Merck Says Injectable Keytruda Succeeded in Late-stage Trial
Express News | Merck Shares up 1.2% Premarket After Trial Shows Injectable Version of Co's Topselling Cancer Drug Keytruda on Par With IV Form
Merck Says Blockbuster Cancer Drug Met Main Goals in Trial of New Under-the-skin Formulation
Merck Reports Topline Results From Pivotal Phase 3 MK-3475A-D77 Trial; Says Trial Met Its Dual Primary Pharmacokinetic Endpoints
Merck Announces Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Express News | Merck: Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa Met Primary Endpoints
Jim Cramer Says Merck & Co., Inc. (MRK) Is 'Just Way Too Hated'
S&P Sees Some Signs of a US Credit Bubble as Spreads Tighten